HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, will be hosting its fourth quarter 2014 financial results and analyst day in New York City on Friday, March 13, 2015 from 10:00 a.m. to 12:00 p.m. ET.
Spectrum’s management and external experts will provide an update on the Company's business and discuss the Company’s development portfolio.
Spectrum speakers scheduled to present include:
Rajesh Shrotriya, M.D., Chairman of the Board and Chief Executive Officer
Joseph Turgeon, President and Chief Operating Officer
Kurt Gustafson, Executive Vice President, Chief Financial Officer and Principal Accounting Officer
Lee Allen, M.D., Chief Medical Officer
Tom Riga, Senior Vice President and Chief Commercial Officer
Four external key opinion leaders scheduled to present include:
Francisco Esteva, M.D., PhD
Professor of Medicine, Director, Breast Medical Oncology Associate, Director of Clinical Investigation, Laura and Isaac Perlmutter Cancer Center New York University Langone Medical Center.
Parameswaran Hari, M.D., MRCP, MS
Armand J. Quick/William F. Stapp Professor of Hematology at the Medical College of Wisconsin, Director of the Adult Blood and Marrow Transplant Program at Froedtert Hospital and the Section Head of Hematologic Malignancies and Transplantation, in the Division of Hematology and Oncology in the Department of Medicine.
Jeffrey L. Vacirca, M.D., FACP
CEO, Managing Partner & Chief of Clinical Research at North Shore Hematology/Oncology Associates Medical Director for ION/ASBSG Vice-President, Community Oncology Alliance CEO & President National Translational Research Group.
Prof Dr. JA Witjes, M.D., PhD
Staff Member in the Department of Urology, The Radboud University Nijmegen Medical Center, Member of the Faculty of the European School of Urology and Chair of the Dutch Guidelines Committee on Bladder Cancer and the EAU Guidelines Committee on Metastatic and Muscle-Invasive Bladder Cancer.
Friday, March 13, 2015 @ 10:00 a.m. Eastern/7:00 a.m. Pacific
(877) 837-3910, Conference ID# 82077760
(973) 796-5077, Conference ID# 82077760
For interested individuals unable to join the call, a replay will be available from March 13, 2015 @ 2:00 p.m. ET/11:00 a.m. PT through March 26, 2015 until 11:59 p.m. ET/8:59 p.m. PT.
|Domestic Replay Dial-In #:||
(855) 859-2056, Conference ID# 82077760
|International Replay Dial-In #:||
(404) 537-3406, Conference ID# 82077760
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on March 13, 2015 at 10:00 a.m. Eastern/7:00 a.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market five oncology drugs─ FUSILEV® (levoleucovorin) for Injection in the U.S.; FOLOTYN® (pralatrexate injection), also marketed in the U.S.; ZEVALIN® (ibritumomab tiuxetan) Injection for intravenous use, for which the Company has worldwide marketing rights; MARQIBO® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion, for which the Company has worldwide marketing rights and BELEODAQ® (belinostat) for Injection in the U.S.. Spectrum's strong track record in in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, and BELEODAQ® are registered trademarks of Spectrum Pharmaceuticals, Inc and its affiliates. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2015 Spectrum Pharmaceuticals, Inc. All Rights Reserved